Latest TRUSCREEN (ASX:TRU) News

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

TruScreen Group Limited has announced a placement of over 1.7 million shares to settle marketing invoices and provide an equity incentive to its CFO, signaling strategic capital management ahead of its next growth phase.

TruScreen Group Limited has corrected an administrative error in its Share Purchase Plan allocations, ensuring shareholders receive their proper pro-rata entitlements ahead of a key special meeting.

TruScreen Group Limited has successfully raised NZ$2.35 million through a share placement, attracting new institutional investors from Asia, while launching a discounted share purchase plan for existing shareholders.

TruScreen Limited has obtained a waiver from NZ RegCo allowing it to allot oversubscribed shares up to 10 business days after its capital raising offer closes, subject to shareholder approval. This move aims to streamline the company’s NZ$3 million placement and share purchase plan.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.